RE104 not checked

Reunion Neuroscience Inc

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
4 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Single dose (Part A) or Repeat-dose (Part B), subcutaneous injection(s) of RE104 for Injection”In the company’s words, NCT07489651 on ClinicalTrials.gov
Tested for
Adjustment Disorder, Generalized Anxiety Disorder
Main trialPhase 2
“The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.”In the company’s words, NCT07002034 on ClinicalTrials.gov

Other drugs for Adjustment Disorder

All 3 drugs for Adjustment Disorder

Coming up2

Changes1

Last 90 days

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Apr 2027 RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Phase 2Recruiting Jul 2027 RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Phase 2Completed 22 May 2025 RE104 Safety and Efficacy Study in Postpartum Depression
Phase 1Completed 28 May 2025 RE104 Clinical Lactation Study
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow RE104

Following is part of Solo: you see every change to RE104 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in